| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Elite Pharmaceuticals Inc (OTCQB: ELTP)
ELTP Technical Analysis
5
| As on 9th Jun 2023 ELTP SHARE Price closed @ 0.03 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.04 & Strong Sell for SHORT-TERM with Stoploss of 0.04 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ELTPSHARE Price
| Open | 0.04 | Change | Price | % |
| High | 0.04 | 1 Day | -0.01 | -25.00 |
| Low | 0.03 | 1 Week | 0.00 | 0.00 |
| Close | 0.03 | 1 Month | 0.00 | 0.00 |
| Volume | 824154 | 1 Year | -0.01 | -25.00 |
| 52 Week High 0.05 | 52 Week Low 0.03 | ||||
OTCQB USA Most Active Stocks
| BMIX | 0.01 | % |
| MOBQ | 0.18 | -5.26% |
| FNMA | 0.45 | 0.00% |
| ALPP | 3.56 | -0.80% |
| ALPP | 3.56 | -0.80% |
| SHMP | 0.06 | 0.00% |
| NWBO | 0.73 | 0.00% |
| VPLM | 0.08 | % |
| NLST | 3.72 | -8.60% |
| SRNA | 2.78 | 14.88% |
OTCQB USA Top Gainers Stocks
OTCQB USA Top Losers Stocks
| ELTP Daily Charts |
ELTP Intraday Charts |
Whats New @ Bazaartrend |
ELTP Free Analysis |
|
|
ELTP Important Levels Intraday
| RESISTANCE | 0.05 |
| RESISTANCE | 0.04 |
| RESISTANCE | 0.04 |
| RESISTANCE | 0.04 |
| SUPPORT | 0.02 |
| SUPPORT | 0.02 |
| SUPPORT | 0.02 |
| SUPPORT | 0.01 |
ELTP Forecast April 2024
| 4th UP Forecast | 0.07 |
| 3rd UP Forecast | 0.06 |
| 2nd UP Forecast | 0.05 |
| 1st UP Forecast | 0.04 |
| 1st DOWN Forecast | 0.02 |
| 2nd DOWN Forecast | 0.01 |
| 3rd DOWN Forecast | 0 |
| 4th DOWN Forecast | -0.01 |
ELTP Weekly Forecast
| 4th UP Forecast | 0.05 |
| 3rd UP Forecast | 0.04 |
| 2nd UP Forecast | 0.04 |
| 1st UP Forecast | 0.04 |
| 1st DOWN Forecast | 0.02 |
| 2nd DOWN Forecast | 0.02 |
| 3rd DOWN Forecast | 0.02 |
| 4th DOWN Forecast | 0.01 |
ELTP Forecast2024
| 4th UP Forecast | 0.07 |
| 3rd UP Forecast | 0.06 |
| 2nd UP Forecast | 0.05 |
| 1st UP Forecast | 0.04 |
| 1st DOWN Forecast | 0.02 |
| 2nd DOWN Forecast | 0.01 |
| 3rd DOWN Forecast | 0 |
| 4th DOWN Forecast | -0.01 |
Elite Pharmaceuticals Inc ( OTCQB USA Symbol : ELTP )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ELTP Business Profile
Elite Pharmaceuticals, Inc. engages in the research, development, manufacture, and licensing of proprietary orally administered controlled-release drug delivery systems and products. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets for the treatment of bariatrics under Adipex-P brand; Hydromorphone HCl 8mg tablets for pains under the Dilaudid brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Oxycodone HCl immediate release 5mg, 10mg, 15mg, 20mg, and 30mg tablets for pains under Roxycodone brand; Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Methadone HCl tablets for pains under the Dolophine brand; and Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets for central nervous system diseases under the Adderall brand, as well as Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; and SequestOX, an immediate release Oxycodone with Naltrexone. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, and infection. Further, the company is developing a range of abuse deterrent opioid products. It has a manufacturing and license agreement with Epic Pharma LLC; development and license agreement with SunGen Pharma, LLC; and strategic marketing alliance with Glenmark Pharmaceuticals, Inc. USA, as well as Lannett Company. Inc. The company was founded in 1984 and is headquartered in Northvale, New Jersey. Address: 165 Ludlow Avenue, Northvale, NJ, United States, 07647
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service